CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended				71 Months Ended
	Mar. 31, 2013		Mar. 31, 2012		Mar. 31, 2013
Revenue	$ 0		$ 0		$ 0
Operating expense
General & administrative	239,811	[1]	231,314	[1]	7,299,273	[1]
Total operating expense	655,910		522,627		13,104,589
Net operating loss	(655,910)		(522,627)		(13,104,589)
Other income (expense)
Interest income	124		529		77,213
Other income	0		0		244,479
Other expense	(216)		(129)		(4,390)
Total Other Income (Expense)	(92)		400		317,302
Net Loss	(656,002)		(522,227)		(12,787,287)
Loss per share
Net loss per share, basic and diluted	$ (0.01)		$ (0.01)		$ (0.27)
Basic and diluted weighted average number of common shares outstanding	62,219,050		58,381,419		46,728,530
All Other
Operating expense
Research and development	401,099	[2]	279,613	[2]	4,726,696	[2]
MD Anderson for License
Operating expense
Research and development	$ 15,000	[3]	$ 11,700	[3]	$ 1,078,620	[3]

[1] General & administrative expense includes stock option expense of $4,605 and $1,950 for the quarters ending 3/31/2013 and 3/31/2012, respectively; and for the period from inception through 3/31/2013, $2,595,361 for stock option and warrant expense and $318,500 in stock for services.

[2] Research and development expense includes stock option expense of $11,414 and $17,406 for the quarters ending 3/31/2013 and 3/31/2012, respectively; and $434,412 for the period from inception through 3/31/2013. Research and development expense also includes amortization expense of $40,156 and $48,109 for the quarters ending 3/31/2013 and 3/31/2012, respectively; and $1,016,891 for the period from inception through 3/31/2013.

[3] Includes $690,000 technology impairment charge for the period from inception through 3/31/2013.